The following complications were seen: Graft failure: Probability after 90 days from HSCT was 10%, probability of engraftment was 92% in HLA-matched, and 72% in mismatched donor. GVHD: Cumulative incidence at 90 days (grade 2-4) was 21%. 2 factors associated with a significant lower rate of GVHD: HLA-matched related donor and double prophylaxis with CSA and MTX. Peripheral blood as sources of HSCT was associated with higher cGvHD incidence.

Overall Survival: 3-year OS after HSCT 82%. Median time from transplant to death: 3 months, with 80% of the deaths occurring within 12 months after transplant. [NW4]Transplants undertaken in later years had better survival (OS-3ys 66% in 1990-2000, 79% 2001-2007 and 91% in 2008-2012). No secondary malignancies were reported.

* HSCT is an option for treatment of SCN with an acceptable 3 year OS and EFS (82% and 71%, respectively). TRM is 17% and therefore appropriate selection of patients and SC sources as well as GVHD prophylaxis are important factors.